|
Therapy-related myelodysplastic syndromes in the genomics era |
Jun 2023 |
Bulletin du Cancer |
Myelodysplastic Syndromes (MDS) |
|
Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes |
Aug 2020 |
Cancer |
Myelodysplastic Syndromes (MDS) |
|
Good but not good enough: Clinical trial participation of patients with myelodysplastic syndromes |
Aug 2020 |
Cancer |
Myelodysplastic Syndromes (MDS) |
|
Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS) |
Jan 2021 |
Cancer Causes & Control : CCC |
Myelodysplastic Syndromes (MDS) |
|
Alcohol use is not a significant contributor to myelodysplastic syndromes |
Apr 2020 |
Cancer Causes & Control : CCC |
Myelodysplastic Syndromes (MDS) |
|
Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options |
Jan 2021 |
Cancer Management and Research |
Myelodysplastic Syndromes (MDS) |
|
Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria. |
Feb 2019 |
Cancer Med |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium |
Dec 2020 |
Cancer Medicine |
Myelodysplastic Syndromes (MDS) |
|
Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) |
Mar 2021 |
Cancers |
Chronic Myelomonocytic Leukaemia (CMML), Myelodysplastic Syndromes (MDS) |
|
The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications |
Nov 2020 |
Cells |
Myelodysplastic Syndromes (MDS) |
